Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 1,865 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Active, not recruiting Not applicable Interventional

Pain and Opioids: Integrated Treatment In Veterans

NCT04648228
View directory record Official record
Conditions
Chronic Pain, Opioid-use Disorder, Opioids; Harmful Use
Interventions
ACT+MBRP, Education control
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
San Francisco, California • Albuquerque, New Mexico • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 28, 2026, 2:33 PM EDT
Active, not recruiting No phase listed Observational

Depression and Adherence in Head and Neck Cancer

NCT00498875
View directory record Official record
Conditions
Oropharyngeal Cancer, Head and Neck Cancer
Interventions
Questionnaire, Depression Intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425
View directory record Official record
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions
NTX-1088, Pembrolizumab
Drug
Lead sponsor
Nectin Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Telephone Reminiscence Intervention on Mental Health

NCT07576855
View directory record Official record
Conditions
Mental Health
Interventions
Telephone Reminiscence Program
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
60 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Completed No phase listed Observational

Colorectal Cancer (CRC) Surveillance Tool: Cognitive and Pilot Testing

NCT03180411
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 28, 2026, 2:33 PM EDT
Not listed No phase listed Observational

Testing Accountability in Patient Adherence

NCT01844557
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Swallowing Exercises, Symptom Inventory, Questionnaires
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 28, 2026, 2:33 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT06636175
View directory record Official record
Conditions
Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Interventions
64Cu-LLP2A, PET/CT
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Active, not recruiting No phase listed Observational

Nashville Early Diagnosis Lung Cancer Project

NCT01475500
View directory record Official record
Conditions
Lung Cancer
Interventions
Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection
Procedure · Radiation · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
55 Years to 80 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Neural Correlates of Lidocaine Analgesia

NCT05501600
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Peripheral Nerve Stimulation, Lidocaine IV
Device · Drug
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Not applicable Interventional

Guided Self-Help for Binge Eating Disorder

NCT01282736
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
Integrative Response Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 28, 2026, 2:33 PM EDT
Recruiting Phase 3 Interventional

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
87
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Phase 2Phase 3 Interventional

Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint

NCT03580707
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
BRV vs LEV in randomized double blinded, crossover fashion
Drug
Lead sponsor
Rosenfeld, William E., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 28, 2026, 2:33 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
41
States / cities
Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Not yet recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

NCT07300475
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC
Drug · Biological · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks

NCT03375099
View directory record Official record
Conditions
Intentional Self-Harm by Other Specified Means
Interventions
Lethal Means Counseling, Health and Stress Reduction
Behavioral
Lead sponsor
University of Southern Mississippi
Other
Eligibility
18 Years to 60 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 28, 2026, 2:33 PM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

Peer Approaches to Lupus Self-management

NCT03734055
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Quality of Life, Behavior, Health
Interventions
Peer Mentoring, Social Support Group
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 28, 2026, 2:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117
View directory record Official record
Conditions
Solid Tumor, MET Alteration
Interventions
VERT-002
Drug
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Canton, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 28, 2026, 2:33 PM EDT
Terminated Phase 1 Interventional

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

NCT05769959
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions
RO7515629, tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 28, 2026, 2:33 PM EDT
Active, not recruiting Phase 2 Interventional

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

NCT02862938
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501 ECT implant, Sham
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 28, 2026, 2:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Feasibility and Preliminary Effects of Yoga on Excessive Gestational Weight Gain

NCT03893708
View directory record Official record
Conditions
Weight Gain
Interventions
Prenatal yoga, Pregnancy education
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 28, 2026, 2:33 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171, Carboplatin, Cisplatin, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin, Carboplatin/Paclitaxel, Volrustomig, Rilvegostomig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 95 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 2:33 PM EDT
Not listed Phase 1Phase 2 Interventional

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

NCT03797391
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
Interventions
EMB-01
Drug
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Detroit, Michigan • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 28, 2026, 2:33 PM EDT